Latest Ratios: P/E Ratio -3.9x · EV/EBITDA N/A · ROE -317.6%. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $45M | $42M | $122M | — | — | — |
| Enterprise Value | $37M | $35M | $121M | — | — | — |
| P/E Ratio → | -3.94 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | 6.96 | 7.12 | 189.26 | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | -317.6% | -317.6% | -810.2% | -1045.4% | — | — |
| ROA | -240.3% | -240.3% | -542.3% | -542.1% | -1646.9% | -251.1% |
| ROIC | — | — | -610.4% | -185.9% | — | — |
| ROCE | -321.5% | -321.5% | -599.9% | -315.2% | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.15 | 0.03 | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.23 | -1.82 | 0.03 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | — | — | -2.81 | -6.96 | — | — |
Net cash position: cash ($7M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 5.14 | 5.14 | 1.94 | 0.33 | 0.05 | — |
| Quick Ratio | 5.14 | 5.14 | 1.94 | 0.33 | 0.05 | — |
| Cash Ratio | 5.10 | 5.10 | 1.86 | 0.00 | 0.00 | — |
| Asset Turnover | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $32M | $30M | $30M | $30M | $30M |
Binary clinical trial failure
As reported in financial statements, TELO's price-to-book ratio of 6.74 suggests a significant premium relative to its tangible asset base, which appears disconnected from the company's pre-clinical status and the absence of any commercialized revenue streams to justify such a valuation multiple.
The current valuation appears to be driven entirely by speculative interest in the longevity sector rather than underlying financial performance. Investors should monitor whether this premium can be sustained as the company approaches critical clinical milestones, as any delay in IND clearance could lead to a rapid compression of these multiples.
Based on historical data, TELO's ROIC of -87.4% in 2024Q1 highlights the extreme inefficiency of capital deployment during the early stages of drug development, where the company is consuming resources at a rate that far outpaces any potential for near-term value creation or return generation.
The persistent negative returns on capital are characteristic of a pre-revenue biotech firm, yet the magnitude of these losses warrants further investigation into the company's cost-control mechanisms. The lack of positive ROIC suggests that the company is currently destroying shareholder value as it attempts to validate its core intellectual property.
According to recent SEC filings, TELO's current ratio has fluctuated significantly, dropping from 7.20 in 2024Q1 to 7.00 in 2026Q1, which masks the underlying reality that the company's absolute cash reserves are dwindling rapidly in the face of ongoing, non-discretionary research and development expenditures.
While the current ratio appears superficially healthy, it is misleading for a company with no revenue and high fixed costs. The rapid depletion of cash suggests that the company's liquidity position is highly vulnerable to any unforeseen regulatory delays or increases in clinical trial costs.
As indicated by the provided financial data, the use of P/E ratios for TELO is fundamentally flawed, as the company's negative earnings and lack of revenue render traditional valuation multiples entirely meaningless for assessing the intrinsic value of its pre-clinical intellectual property portfolio.
Investors should instead focus on cash-burn-to-milestone metrics or the probability-adjusted net present value of the TELOMIR-1 pipeline. Relying on P/E or EV/EBITDA ratios in this context obscures the binary nature of the company's risk profile and may lead to an inaccurate assessment of its long-term viability.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TELO stock.
Telomir Pharmaceuticals, Inc. Common Stock's current P/E ratio is -3.9x. This places it at the 50th percentile of its historical range.
Telomir Pharmaceuticals, Inc. Common Stock's return on equity (ROE) is -317.6%. The historical average is -317.6%.
Based on historical data, Telomir Pharmaceuticals, Inc. Common Stock is trading at a P/E of -3.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.